Revance Therapeutics, Inc. (RVNC)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 11:11AM EDT. Market open.
| Previous close | 4.2900 |
| Open | 4.0500 |
| Bid | 3.0000 x 500 |
| Ask | 3.1000 x 200 |
| Day's range | 3.0000 - 4.0500 |
| 52-week range | 3.0000 - 35.8300 |
| Volume | |
| Avg. volume | 1,846,272 |
| Market cap | 323.07M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.8300 |
| Earnings date | 05 Aug 2024 - 20 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.91 |
ZacksRevance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of 18.18% and 6.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
NASHVILLE, Tenn., May 09, 2024--Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
- Business Wire
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
NASHVILLE, Tenn., May 09, 2024--Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
© 2024 Yahoo. All rights reserved.